$LAB
Wall Street analysts expect Standard BioTools (NASDAQ' LAB) stock to hit $1.55 per share on average within the next 12 months. The lowest estimated price is $1.35 while the highest is $1.75. At the moment, shares are priced at $0.88, which means that the stock has a potential upside of 76%.
Below are the details about the projections.
Analyst Recommendations, The Wall Street has issued a Hold/Reduce rating on the stock while one firm has a Strong Buy rating on the shares. Other analysts remained cautious about the stock ahead of the quarterly earnings report.
Revenue Forecast, Standard BioTools has guided that its revenue in fiscal 2026 will be between $80 million and $85 million.
Past Performance & Volatility, Standard BioTools stock has been running near the bottom of the 52-week range and the shares have become extremely volatile as the firm battles to curb the slide in revenue and deal with the downard revision of profit forecasts.
Wall Street analysts expect Standard BioTools (NASDAQ' LAB) stock to hit $1.55 per share on average within the next 12 months. The lowest estimated price is $1.35 while the highest is $1.75. At the moment, shares are priced at $0.88, which means that the stock has a potential upside of 76%.
Below are the details about the projections.
Analyst Recommendations, The Wall Street has issued a Hold/Reduce rating on the stock while one firm has a Strong Buy rating on the shares. Other analysts remained cautious about the stock ahead of the quarterly earnings report.
Revenue Forecast, Standard BioTools has guided that its revenue in fiscal 2026 will be between $80 million and $85 million.
Past Performance & Volatility, Standard BioTools stock has been running near the bottom of the 52-week range and the shares have become extremely volatile as the firm battles to curb the slide in revenue and deal with the downard revision of profit forecasts.